Unknown

Dataset Information

0

Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients.


ABSTRACT: Prior research strongly implicates gastric acid and bile acids, two major components of the gastroesophageal refluxate, in the development of Barrett's esophagus and its pathogenesis. Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, has been shown to protect esophageal cells against oxidative stress induced by cytotoxic bile acids. We conducted a pilot clinical study to evaluate the clinical activity of UDCA in patients with Barrett's esophagus. Twenty-nine patients with Barrett's esophagus received UDCA treatment at a daily dose of 13 to 15 mg/kg/day for 6 months. The clinical activity of UDCA was assessed by evaluating changes in gastric bile acid composition and markers of oxidative DNA damage (8-hydroxydeoxyguanosine), cell proliferation (Ki67), and apoptosis (cleaved caspase-3) in Barrett's esophagus epithelium. The bile acid concentrations in gastric fluid were measured by liquid chromatography/mass spectrometry. At baseline, UDCA (sum of unchanged and glycine/taurine conjugates) accounted for 18.2% of total gastric bile acids. After UDCA intervention, UDCA increased significantly to account for 93.4% of total gastric bile acids (P < 0.0001). The expression of markers of oxidative DNA damage, cell proliferation, and apoptosis was assessed in the Barrett's esophagus biopsies by IHC. The selected tissue biomarkers were unchanged after 6 months of UDCA intervention. We conclude that high-dose UDCA supplementation for 6 months resulted in favorable changes in gastric bile acid composition but did not modulate selected markers of oxidative DNA damage, cell proliferation, and apoptosis in the Barrett's esophagus epithelium. Cancer Prev Res; 9(7); 528-33. ©2016 AACRSee related article by Brian J. Reid, p. 512.

SUBMITTER: Banerjee B 

PROVIDER: S-EPMC4930711 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients.

Banerjee Bhaskar B   Shaheen Nicholas J NJ   Martinez Jessica A JA   Hsu Chiu-Hsieh CH   Trowers Eugene E   Gibson Blake A BA   Della'Zanna Gary G   Richmond Ellen E   Chow H-H Sherry HH  

Cancer prevention research (Philadelphia, Pa.) 20160223 7


Prior research strongly implicates gastric acid and bile acids, two major components of the gastroesophageal refluxate, in the development of Barrett's esophagus and its pathogenesis. Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, has been shown to protect esophageal cells against oxidative stress induced by cytotoxic bile acids. We conducted a pilot clinical study to evaluate the clinical activity of UDCA in patients with Barrett's esophagus. Twenty-nine patients with Barrett's esophagus  ...[more]

Similar Datasets

| S-EPMC4101678 | biostudies-literature
2006-06-28 | E-GEOD-5155 | biostudies-arrayexpress
| S-EPMC6684532 | biostudies-other
2006-06-28 | GSE5155 | GEO
| S-EPMC2906782 | biostudies-literature
| S-EPMC4336231 | biostudies-literature
| S-EPMC7350268 | biostudies-literature
| S-EPMC3811010 | biostudies-literature
| S-EPMC5962402 | biostudies-literature
| S-EPMC7001889 | biostudies-literature